144 related articles for article (PubMed ID: 8633403)
1. Determining prognosis of clinically localized prostate cancer by immunohistochemical detection of mutant p53.
Stricker HJ; Jay JK; Linden MD; Tamboli P; Amin MB
Urology; 1996 Mar; 47(3):366-9. PubMed ID: 8633403
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical expression of retinoblastoma and p53 tumor suppressor genes in prostatic intraepithelial neoplasia: comparison with prostatic adenocarcinoma and benign prostate.
Tamboli P; Amin MB; Xu HJ; Linden MD
Mod Pathol; 1998 Mar; 11(3):247-52. PubMed ID: 9521470
[TBL] [Abstract][Full Text] [Related]
3. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO
J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
[TBL] [Abstract][Full Text] [Related]
4. p53, bcl-2 and retinoblastoma proteins as long-term prognostic markers in localized carcinoma of the prostate.
Theodorescu D; Broder SR; Boyd JC; Mills SE; Frierson HF
J Urol; 1997 Jul; 158(1):131-7. PubMed ID: 9186339
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of p53 nuclear accumulation in localized prostate cancer treated with radical prostatectomy.
Quinn DI; Henshall SM; Head DR; Golovsky D; Wilson JD; Brenner PC; Turner JJ; Delprado W; Finlayson JF; Stricker PD; Grygiel JJ; Sutherland RL
Cancer Res; 2000 Mar; 60(6):1585-94. PubMed ID: 10749127
[TBL] [Abstract][Full Text] [Related]
6. Androgen receptor expression in prostate cancer lymph node metastases is predictive of outcome after surgery.
Sweat SD; Pacelli A; Bergstralh EJ; Slezak JM; Cheng L; Bostwick DG
J Urol; 1999 Apr; 161(4):1233-7. PubMed ID: 10081876
[TBL] [Abstract][Full Text] [Related]
7. Prediction of biochemical relapse for stage pT3 prostate cancer following radical prostatectomy.
Wu TT; Wang JS; Lu CM; Lee YH; Huang JK
Zhonghua Yi Xue Za Zhi (Taipei); 2000 Feb; 63(2):124-30. PubMed ID: 10677923
[TBL] [Abstract][Full Text] [Related]
8. Preoperative p53, bcl-2, CD44 and E-cadherin immunohistochemistry as predictors of biochemical relapse after radical prostatectomy.
Brewster SF; Oxley JD; Trivella M; Abbott CD; Gillatt DA
J Urol; 1999 Apr; 161(4):1238-43. PubMed ID: 10081877
[TBL] [Abstract][Full Text] [Related]
9. BCL-2 and p53 expression in clinically localized prostate cancer predicts response to external beam radiotherapy.
Scherr DS; Vaughan ED; Wei J; Chung M; Felsen D; Allbright R; Knudsen BS
J Urol; 1999 Jul; 162(1):12-6; discussion 16-7. PubMed ID: 10379729
[TBL] [Abstract][Full Text] [Related]
10. The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy.
Sebo TJ; Bock BJ; Cheville JC; Lohse C; Wollan P; Zincke H
J Urol; 2000 Jan; 163(1):174-8. PubMed ID: 10604340
[TBL] [Abstract][Full Text] [Related]
11. p53 nuclear protein expression is an independent prognostic marker in clinically localized prostate cancer patients undergoing radical prostatectomy.
Bauer JJ; Sesterhenn IA; Mostofi KF; McLeod DG; Srivastava S; Moul JW
Clin Cancer Res; 1995 Nov; 1(11):1295-300. PubMed ID: 9815924
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of DNA ploidy, bcl-2 and p53 in localized prostate adenocarcinoma incidentally discovered at transurethral prostatectomy.
Abaza R; Diaz LK; Laskin WB; Pins MR
J Urol; 2006 Dec; 176(6 Pt 1):2701-5. PubMed ID: 17085199
[TBL] [Abstract][Full Text] [Related]
13. Perineural invasion and seminal vesicle involvement predict pelvic lymph node metastasis in men with localized carcinoma of the prostate.
Stone NN; Stock RG; Parikh D; Yeghiayan P; Unger P
J Urol; 1998 Nov; 160(5):1722-6. PubMed ID: 9783940
[TBL] [Abstract][Full Text] [Related]
14. Caveolin-1 expression is a predictor of recurrence-free survival in pT2N0 prostate carcinoma diagnosed in Japanese patients.
Satoh T; Yang G; Egawa S; Addai J; Frolov A; Kuwao S; Timme TL; Baba S; Thompson TC
Cancer; 2003 Mar; 97(5):1225-33. PubMed ID: 12599229
[TBL] [Abstract][Full Text] [Related]
15. Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer.
Kupelian P; Katcher J; Levin H; Zippe C; Klein E
Urology; 1996 Aug; 48(2):249-60. PubMed ID: 8753737
[TBL] [Abstract][Full Text] [Related]
16. Visual estimation of tumour extent is not an independent predictor of prostate specific antigen recurrence.
Jones TD; Koch MO; Lin H; Cheng L
BJU Int; 2005 Dec; 96(9):1253-7. PubMed ID: 16287440
[TBL] [Abstract][Full Text] [Related]
17. [Recurrence following radical surgery for prostatic cancer. Analysis of clinical, biological and anatomo-pathological prognostic factors].
Feyaerts A; Delrée A; Lorge F; Opsomer RJ; Wese FX; Van Cangh PJ; Draguet AP; Cosyns JP
Acta Urol Belg; 1997 Mar; 65(1):11-8. PubMed ID: 9245198
[TBL] [Abstract][Full Text] [Related]
18. Preoperative serum prostate specific antigen does not reflect biochemical failure rates after radical prostatectomy in men with large volume cancers.
Noguchi M; Stamey TA; McNeal JE; Yemoto CM
J Urol; 2000 Nov; 164(5):1596-600. PubMed ID: 11025712
[TBL] [Abstract][Full Text] [Related]
19. Pathological parameters of radical prostatectomy for clinical stages T1c versus T2 prostate adenocarcinoma: decreased pathological stage and increased detection of transition zone tumors.
Jack GS; Cookson MS; Coffey CS; Vader V; Roberts RL; Chang SS; Smith JA; Shappell SB
J Urol; 2002 Aug; 168(2):519-24. PubMed ID: 12131301
[TBL] [Abstract][Full Text] [Related]
20. Preoperative neural network using combined magnetic resonance imaging variables, prostate-specific antigen, and gleason score for predicting prostate cancer biochemical recurrence after radical prostatectomy.
Poulakis V; Witzsch U; de Vries R; Emmerlich V; Meves M; Altmannsberger HM; Becht E
Urology; 2004 Dec; 64(6):1165-70. PubMed ID: 15596191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
